Drug – bio-affecting and body treating compositions – In vivo diagnosis or in vivo testing – Testing efficacy or toxicity of a compound or composition
Reexamination Certificate
2006-05-19
2009-10-13
Saunders, David A (Department: 1644)
Drug, bio-affecting and body treating compositions
In vivo diagnosis or in vivo testing
Testing efficacy or toxicity of a compound or composition
C435S007210, C435S007230, C435S007240, C435S007800, C435S962000, C436S178000, C436S824000, C436S825000
Reexamination Certificate
active
07601335
ABSTRACT:
The present application describes a method for pretreating a biological sample from an autoimmune disease subject in order to avoid interference, especially where the sample is to be subjected to a cell-based biological activity assay, such as a neutralizing antibody assay.
REFERENCES:
patent: 4690905 (1987-09-01), Diamond
patent: 4861579 (1989-08-01), Meyer et al.
patent: 5500362 (1996-03-01), Robinson et al.
patent: 5565332 (1996-10-01), Hoogenboom et al.
patent: 5573905 (1996-11-01), Lerner et al.
patent: 5595721 (1997-01-01), Kaminski et al.
patent: 5677180 (1997-10-01), Robinson et al.
patent: 5693780 (1997-12-01), Newman et al.
patent: 5721108 (1998-02-01), Robinson et al.
patent: 5736137 (1998-04-01), Anderson et al.
patent: 5776456 (1998-07-01), Anderson et al.
patent: 5843398 (1998-12-01), Kaminski et al.
patent: 5843439 (1998-12-01), Anderson et al.
patent: 5849898 (1998-12-01), Seed et al.
patent: 6015542 (2000-01-01), Kaminski et al.
patent: 6090365 (2000-07-01), Kaminski et al.
patent: 6120767 (2000-09-01), Robinson et al.
patent: 6171586 (2001-01-01), Lam et al.
patent: 6194551 (2001-02-01), Idusogie et al.
patent: 6224866 (2001-05-01), Barbera-Guillem
patent: 6242195 (2001-06-01), Idusogie et al.
patent: 6287537 (2001-09-01), Kaminski et al.
patent: 6306393 (2001-10-01), Goldenberg
patent: 6368596 (2002-04-01), Ghetie et al.
patent: 6399061 (2002-06-01), Anderson et al.
patent: 6410391 (2002-06-01), Zelsacher
patent: 6455043 (2002-09-01), Grillo-Lopez
patent: 6528624 (2003-03-01), Idusogie et al.
patent: 6538124 (2003-03-01), Idusogie et al.
patent: 6565827 (2003-05-01), Kaminski et al.
patent: 6652852 (2003-11-01), Robinson et al.
patent: 6682734 (2004-01-01), Anderson et al.
patent: 6726909 (2004-04-01), Williams
patent: 6737056 (2004-05-01), Presta
patent: 6846476 (2005-01-01), White
patent: 6893625 (2005-05-01), Robinson et al.
patent: 6896885 (2005-05-01), Hanna
patent: 6897044 (2005-05-01), Braslawsky et al.
patent: 2001/0018041 (2001-08-01), Hanna et al.
patent: 2001/0056066 (2001-12-01), Bugelski et al.
patent: 2002/0004587 (2002-01-01), Miller et al.
patent: 2002/0006404 (2002-01-01), Hanna et al.
patent: 2002/0009427 (2002-01-01), Wolin et al.
patent: 2002/0009444 (2002-01-01), Grillo-Lopez
patent: 2002/0012665 (2002-01-01), Hanna
patent: 2002/0041847 (2002-04-01), Goldenberg
patent: 2002/0058029 (2002-05-01), Hanna
patent: 2002/0128488 (2002-09-01), Yamakawa et al.
patent: 2002/0136719 (2002-09-01), Shenoy et al.
patent: 2002/0197255 (2002-12-01), Anderson et al.
patent: 2002/0197256 (2002-12-01), Grewal
patent: 2003/0021781 (2003-01-01), Anderson et al.
patent: 2003/0026801 (2003-02-01), Weiner et al.
patent: 2003/0026804 (2003-02-01), Grillo-Lopez et al.
patent: 2003/0068664 (2003-04-01), Albitar et al.
patent: 2003/0082172 (2003-05-01), Anderson et al.
patent: 2003/0095963 (2003-05-01), Anderson et al.
patent: 2003/0103971 (2003-06-01), Hariharan et al.
patent: 2003/0133930 (2003-07-01), Goldenberg et al.
patent: 2003/0147885 (2003-08-01), Anderson et al.
patent: 2003/0157108 (2003-08-01), Presta
patent: 2003/0180292 (2003-09-01), Hanna et al.
patent: 2003/0185796 (2003-10-01), Wolin et al.
patent: 2003/0219433 (2003-11-01), Hansen
patent: 2003/0219818 (2003-11-01), Bohen et al.
patent: 2004/0093621 (2004-05-01), Shitara et al.
patent: 2004/0202658 (2004-10-01), Benyunes
patent: 2004/0213784 (2004-10-01), Grillo-Lopez et al.
patent: 2005/0025764 (2005-02-01), Watkins et al.
patent: 2005/0032130 (2005-02-01), Beresini et al.
patent: 2005/0053602 (2005-03-01), Brunetta
patent: 2005/0069545 (2005-03-01), Carr et al.
patent: 2005/0079174 (2005-04-01), Barbera-Guillen et al.
patent: 2005/0106108 (2005-05-01), Leung et al.
patent: 2005/0112060 (2005-05-01), White
patent: 2005/0123540 (2005-06-01), Hanna et al.
patent: 2005/0123546 (2005-06-01), Umana et al.
patent: 2005/0180972 (2005-08-01), Wahl et al.
patent: 2005/0186216 (2005-08-01), Ledbetter et al.
patent: 2006/0263349 (2006-11-01), McCutcheon et al.
patent: 2007/0099245 (2007-05-01), Gorovits et al.
patent: 10060686 (2002-06-01), None
patent: 0 332 865 (1989-09-01), None
patent: 0 330 191 (1996-10-01), None
patent: WO 92/21031 (1992-11-01), None
patent: WO 95/03770 (1995-02-01), None
patent: WO 98/56418 (1998-12-01), None
patent: WO 98/58964 (1998-12-01), None
patent: WO 99/22764 (1999-05-01), None
patent: WO 99/51642 (1999-10-01), None
patent: WO 00/09160 (2000-02-01), None
patent: WO 00/20864 (2000-04-01), None
patent: WO 00/27428 (2000-05-01), None
patent: WO 00/27433 (2000-05-01), None
patent: WO 00/42072 (2000-07-01), None
patent: WO 00/44788 (2000-08-01), None
patent: WO 00/61739 (2000-10-01), None
patent: WO 00/67795 (2000-11-01), None
patent: WO 00/67796 (2000-11-01), None
patent: WO 00/74718 (2000-12-01), None
patent: WO 00/76542 (2000-12-01), None
patent: WO 01/03734 (2001-01-01), None
patent: WO 01/10460 (2001-02-01), None
patent: WO 01/10461 (2001-02-01), None
patent: WO 01/10462 (2001-02-01), None
patent: WO 01/13945 (2001-03-01), None
patent: WO 01/29246 (2001-04-01), None
patent: WO 01/34194 (2001-05-01), None
patent: WO 01/72333 (2001-10-01), None
patent: WO 01/74388 (2001-10-01), None
patent: WO 01/77342 (2001-10-01), None
patent: WO 01/80884 (2001-11-01), None
patent: WO 01/97858 (2001-12-01), None
patent: WO 02/04021 (2002-01-01), None
patent: WO 02/16329 (2002-02-01), None
patent: WO 02/24909 (2002-03-01), None
patent: WO 02/34790 (2002-05-01), None
patent: WO 02/38766 (2002-05-01), None
patent: WO 02/056910 (2002-07-01), None
patent: WO 02/060955 (2002-08-01), None
patent: WO 02/079255 (2002-10-01), None
patent: WO 02/092620 (2002-11-01), None
patent: WO 02/096948 (2002-12-01), None
patent: WO 02/102312 (2002-12-01), None
patent: WO 03/002607 (2003-01-01), None
patent: WO 03/024991 (2003-03-01), None
patent: WO 03/053926 (2003-03-01), None
patent: WO 03/049694 (2003-06-01), None
patent: WO 03/061694 (2003-07-01), None
patent: WO 03/068821 (2003-08-01), None
patent: WO 03/085119 (2003-10-01), None
patent: WO 2004/032828 (2004-04-01), None
patent: WO 2004/035607 (2004-04-01), None
patent: WO 2004/056312 (2004-07-01), None
patent: WO 2004/058298 (2004-07-01), None
patent: WO 2004/091657 (2004-10-01), None
patent: WO 2004/103404 (2004-12-01), None
patent: WO 2005/000351 (2005-01-01), None
patent: WO 2005/000901 (2005-01-01), None
patent: WO 2005/014618 (2005-02-01), None
patent: WO 2005/016969 (2005-02-01), None
patent: WO 2005/017529 (2005-02-01), None
patent: WO 2005/044859 (2005-05-01), None
patent: WO 2005/070963 (2005-08-01), None
Christen et al., “Immune response to a recombinant human TNFR55-IgG1 fusion protein: auto-antibodies in rheumatoid arthritis (RA) and multiple sclerosis (MS) patients have neither neutralizing nor agonist activities”Human Immunology60(9):774-790 (Sep. 1999).
Tincani et al., “The anti-β2-glycoprotein I activity in human anti-phospholipid syndrome sera is due to monoreactive low-affinity autoantibodies directed to epitopes located on native β2-glycoprotein I and preserved during species' evolution”Journal of Immunology157(12):5732-5738 (Dec. 15, 1996).
Ahn et al., “Long-term remission from life-threatening hypercoaulable state associated with lupus anticoagulant (LA) following rituximab therapy”Am. J. Hematol.78(2) :127-129 (2005).
Ahn et al., “Severe hypercoabulable state and concomitant life threatening bleeding successfully treated with rituximab”Blood(Abstract #4139) 102(11) :108b (Nov. 16, 2003).
Akashi et. al., “Successful Treatment of Refractory Systemic Lupus Erythematosus with Intravenous Immunoglobulins”J. Rheumatology17:375-379 (1990).
Albert et al., “A Phase 1 trial of Rituximab (Anti-CD20) for treatment of Systemic Lupus Erythematous”Arthritis Rheum.(Abstract #LB9) 48(12) :3659 (Dec. 2003).
Anderson et al., “Expression of Human B Cell-Associated Antigens on Leukemias and Lymphomas: A Model of Human B Cell Differentiation”Blood63(6) :1424-1433 (1984).
Anderson et al., “Revised estimate of the prevalence of multiple sclerosi
McCutcheon Krista
Song An
Genentech Inc.
Lee Wendy M.
Saunders David A
LandOfFree
Pretreatment of a biological sample from an autoimmune... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pretreatment of a biological sample from an autoimmune..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pretreatment of a biological sample from an autoimmune... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4070578